Protara Therapeutics (TARA) Set to Post Quarterly Earnings on Monday

Key Points

• Protara Therapeutics is expected to report Q3 2026 results before the market opens on November 9, with analysts forecasting a loss of approximately $0.37 per share. The company previously reported a $0.36 per-share loss, missing estimates by $0.03.
• TARA shares opened at $2.48, near their 52-week low of $2.28 and well below the 52-week high of $7.82. The company has a market capitalization of about $146.6 million.
• Analyst sentiment is mixed but leans positive, with seven Buy ratings and one Sell rating producing a consensus “Moderate Buy” rating and an average price target of $26.25. Protara’s lead candidate, TARA-002, is being developed primarily for non-muscle-invasive bladder cancer.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) is projected to post its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect Protara Therapeutics to post earnings of ($0.3657) per share for the quarter. Interested persons can check the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 9:30 AM ET.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.03). On average, analysts expect Protara Therapeutics to post ($1.40) EPS for the current fiscal year and ($1.69) EPS for the next fiscal year.

Protara Therapeutics Stock Performance

NASDAQ:TARA opened at $2.48 on Monday. Protara Therapeutics has a 52-week low of $2.28 and a 52-week high of $7.82. The stock's fifty day moving average price is $3.19 and its two-hundred day moving average price is $4.56. The company has a market cap of $146.57 million, a price-to-earnings ratio of -1.84 and a beta of 1.54.

Analysts Set New Price Targets

Several research analysts recently commented on TARA shares. Wall Street Zen upgraded shares of Protara Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday, September 5th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Protara Therapeutics in a report on Thursday, October 15th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Protara Therapeutics in a report on Thursday, October 15th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $26.25.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and other serious diseases. The company's lead product candidate, TARA-002, is an investigational cell-based immunotherapy derived from a proprietary preparation of Streptococcus pyogenes. Protara is evaluating TARA-002 primarily for the treatment of non-muscle-invasive bladder cancer.

Protara has also investigated TARA-002 for lymphatic malformations, rare abnormalities of the lymphatic system that can cause swelling, pain and other complications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.